Verastem, Inc. (NASDAQ:VSTM) Receives $13.63 Consensus PT from Analysts

Verastem, Inc. (NASDAQ:VSTM) has earned an average rating of “Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $13.63.

VSTM has been the subject of several analyst reports. StockNews.com lowered Verastem from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Verastem in a report on Thursday, December 19th. B. Riley increased their price objective on shares of Verastem from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Mizuho raised their target price on shares of Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, December 19th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Verastem in a research report on Friday, January 24th.

Insider Buying and Selling at Verastem

In other Verastem news, CEO Dan Paterson sold 8,568 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $5.24, for a total value of $44,896.32. Following the transaction, the chief executive officer now directly owns 347,581 shares of the company’s stock, valued at $1,821,324.44. This trade represents a 2.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 10,367 shares of company stock valued at $53,990 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Verastem

A number of large investors have recently modified their holdings of VSTM. Balyasny Asset Management L.P. acquired a new position in Verastem during the 4th quarter worth approximately $20,400,000. AIGH Capital Management LLC purchased a new stake in shares of Verastem during the fourth quarter valued at approximately $13,778,000. Stonepine Capital Management LLC acquired a new position in shares of Verastem during the third quarter worth $3,918,000. Rosalind Advisors Inc. purchased a new position in shares of Verastem in the fourth quarter valued at $4,653,000. Finally, Marshall Wace LLP acquired a new stake in Verastem during the 4th quarter valued at $4,103,000. Institutional investors and hedge funds own 88.37% of the company’s stock.

Verastem Stock Down 2.0 %

VSTM stock opened at $5.45 on Friday. The company has a 50 day moving average price of $5.46 and a two-hundred day moving average price of $4.12. The company has a debt-to-equity ratio of 2.77, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market capitalization of $242.56 million, a P/E ratio of -1.71 and a beta of 0.28. Verastem has a one year low of $2.10 and a one year high of $13.82.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.